SUMM.L

Summit Therapeutics Plc
Award of Share Options
24th December 2019, 07:01
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Award of Share Options

Summit Therapeutics plc 
(‘Summit’ or the ‘Company’)

Award of Share Options

Oxford, UK, and Cambridge, MA, US, 24 December 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, announces a grant of options over new ordinary shares of one penny nominal value (‘Ordinary Shares’) on 23 December 2019 to Mr Manmeet Soni, Dr Elaine Stracker and Dr Ventzislav Stefanov. The Company has also made a grant of share options to certain Company employees in line with the Company’s Long Term Incentive Plan.

Share Option Award to Prospective Non-Executive Directors

Mr Soni, Dr Stracker and Dr Stefanov will join the Board as non-executive directors effective upon the close of the subscription and placing to raise approximately $50 million (the “Fundraising”) that was announced by the Company on 6 December 2019. Following a general meeting of shareholders where all resolutions connected to the Fundraising were duly approved, the Fundraising is expected to close at 8.00 am GMT on 24 December 2019. Details of the grant of share options is as follows:

 Number of share options awardedNumber of outstanding share options heldTotal number of ordinary shares heldTotal number of ordinary shares upon the close of the Fundraising% of enlarged issued share capital
Manmeet Soni1,000,0001,000,000NilNilNil
Elaine Stracker1,000,0001,000,000NilNilNil
Ventzislav Stefanov1,000,0001,000,00074,50074,5000.02%
Robert DugganNilNil78,288,205244,445,25572.78%

All options awarded to Mr Soni, Dr Stracker and Dr Stefanov have an exercise price of 21 pence per ordinary share, representing the mid-market closing price on 20 December 2019. The share options will vest in four equal tranches on the first, second, third and fourth anniversaries of the date of the share option grant and will vest in full on 23 December 2023, or sooner on the happening of certain corporate events reflecting the achievement of the Company’s long-term objectives.

Employee Share Option Award

The Company has also granted options over 850,000 Ordinary Shares to employees who have recently joined the Company. These options have an exercise price of 21 pence per share. They will vest in nine equal tranches on a quarterly basis from 23 December 2020 and will vest in full on 23 December 2022, or sooner on the happening of certain corporate events reflecting the achievement of the Company’s long-term objectives.

The exercise price of 21 ­pence per share for the above option grants was the mid-market closing price of the Ordinary Shares on AIM on 20 December 2019.

The maximum number of outstanding share options following the grants referred to above is 23,399,465.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The person responsible for arranging for the release of this announcement on behalf of the Company is Richard Pye, Vice President, Investor Relations and Corporate Affairs.

About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients, and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for C. difficile infection and gonorrhoea and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.

Contacts

Summit  
Glyn Edwards / Richard Pye (UK office)Tel:44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
   
Cairn Financial Advisers LLP (Nominated Adviser)Tel:+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson  


1Details of the persons discharging managerial responsibilities/person closely associated
a)Name
  1. Manmeet Soni
  2. Elaine Stracker
  3. Ventzislav Stefanov
2Reason for the notification
a)Position / status(i)-(iii) Non-Executive Directors
(expected to be effective from 24 December 2019)
b)Initial notification / AmendmentInitial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameSummit Therapeutics plc
b)LEI213800NRW8AOMYMTBD89
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
  
Identification codeGB00BN40HZ01
b)Nature of the transactionsGrant of share options
c)Price(s) and volume(s) Price(s)Volume(s) 
(i)-(iii) 21.0 per share (exercise price)
 

 
  1. 1,000,000
  2. 1,000,000
  3. 1,000,000
 
d)Aggregated information

 

- Aggregated volume

 

- Price		 

 

3,000,000 ordinary shares

 

21.0 pence per share (exercise price)

 
e)Date of the transactions23 December 2019
f)Place of the transactionsOutside a trading venue

-END-

]]>

TwitterFacebookLinkedIn